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Summary
OBJECTIVE: To examine the demographics, evolution and
outcome of patients suffering from malignancies admitted
to a medical intensive care unit.
PATIENTS AND METHODS: Single centre retrospective
cohort study of patients with malignancies. Data on demo-
graphics, diagnosis laboratory tests, provided therapy and
outcome were retrospectively collected. Data was analysed
for differences between patients suffering from solid com-
pared to haematological malignancies as well as for pre-
dictors of one year survival.
RESULTS: A total of 74 consecutive patients with a me-
dian age of 62 years were enrolled. From these, 42 (57%)
suffered from solid and 32 (43%) from haematological ma-
lignancies. In total, 64% of patients with solid malignan-
cies presented with metastatic disease. The main reason for
intensive care unit admission in patients with solid malig-
nancies was acute cardiovascular failure (39%) and infec-
tions in patients with haematological malignancies (38%).
Intensive care unit mortality, hospital mortality and one
year mortality were 26%, 35% and 71% overall; 17%, 29%
and 69% respectively in patients with solid and 38%, 44%
and 73% respectively in patients with haematological ma-
lignancies. Survival was close to 40% in patients with no or
one organ failure. Survival dropped to 20% with 2 and 13%
with ≥3 organs in failure. The number of organs in failure
predicted hospital fatality with an AUCRoc of 0.87.
CONCLUSION: The number of failing organs rather than
malignancy itself drives outcome even in patients with ma-
lignancies. Thus the number of organs in failure rather than
diagnosis should guide intensive care unit management in
patients with malignancies.
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Introduction
Malignancy together with treatment related side effects
cause substantial morbidity and mortality. According to the
2011 Swiss national cancer epidemiology registry, yearly
35,000 subjects out of the 8 million individuals living in
Switzerland are newly diagnosed with cancer (incidence
0.44%/year) and 16,000 die yearly as a direct consequence
of cancer (incidence 0.2% / year). In recent years intens-
ified chemotherapy, transplantation of (autologous) stem
cells as well as biologics such as certain antibodies, for
example, have improved anti-cancer therapy but increased
treatment related complications. Whether intensive care
therapy should be given to patients with malignancies and
the thus often unclear long term prognosis was and still
is controversially discussed. Various studies have been
locked into this question and have found a high in hospital
mortality with only few long-time survivors [1–5]. Patients
with haematological malignancy were identified to have
especially poor outcome [6] and thus many studies have
stratified patients with solid and haematological malignan-
cies. Mechanical ventilation was shown to largely deteri-
orate outcome in haematological patients [7–10] and was
found to almost always result in fatality in patients who re-
ceived bone marrow- or stem cell transplantation [11–17].
This was particularly the case if the pulmonary complica-
tion occurred within fewer than 90 days after transplanta-
tion [18], or occurred after the engraftment period in the
context of graft versus host disease [19]. On the other hand
more recent studies have shown a noticeably better pro-
gnosis for oncology patients after intensive care therapy
[1, 20]. Furthermore, several studies point out that tumour
characteristics don’t necessarily have a prognostic value [6,
21, 22] and that selected patients with malignancy have
ICU outcomes comparable to patients without malignancy
[3].
To learn more about current practice and outcome of pa-
tients with malignancies we conducted a retrospective co-
hort study. In patients with solid and haematological malig-
nancies at our institution we looked at the current base line
characteristics, the therapy they received as well as their
outcome. Data obtained was analysed to identify the most
appropriate indicator to drive ICU treatment in regard to
survival at one year after hospital admission.
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Patient and methods
Patient population and outcome data
The study was conducted at the medical intensive care
unit (ICU) of the Zurich University Hospital, a Swiss 870
bed tertiary care referral hospital. All patients with solid
or haematologic malignancies admitted within a one year
window, starting January 2002 were eligible. Data on
demographics, therapy applied and hospital outcomes was
retrospectively extracted from data collected while treating
the patient using the hospital’s electronic database
(KISIMTM, Cistec®, Switzerland). Only one ICU admission
per patient and time window entered analysis. Outcome
data were obtained from the one year follow-up database
of the ICU. For quality control and benchmark purposes,
ICUs recognised by the Swiss Society of Intensive Care
Medicine have to regularly deliver an anonymised minimal
set of data, which includes ICU and hospital mortality. For
our one year internal quality control we completed this set
of data by assessing the one year mortality. This informa-
tion is routinely obtained via a follow-up telephone call to
the treating physician. The approval for the retrospective
analyses of the data of this study was given by the ethical
committee of the Department of Internal Medicine of the
University Hospital Zurich and was compliant with the De-
claration of Helsinki.
SAPS II and SOFA scoring
Scores were calculated based on data extracted. For
baseline characterisation the simplified acute physiology
score (SAPS II) according to Le Gall et al. [23] was used.
SAPS II is based on the first 24 hours after ICU admission
and reflects the worst performance looking at 12 physiolo-
Figure 1
Relative prevalence of solid and haematological malignancies. Data
is presented as the percentage of specific types of malignancies
among the study population.
gical variables (heart rate, blood pressure, body temperat-
ure, ratio paO2/FiO2, urinary output, creatinine, leucocytes,
potassium, sodium, bicarbonate, bilirubin, Glasgow coma
scale) as well as patients demographics (age, reason for
ICU admission, metastatic tumour, haematological tumour
or AIDS). These parameters allow the calculation of an in-
teger ranging between 0 and 163 and results in a predicted
mortality that is pure statistics. The higher the score, the
higher the predicted mortality.
SAPS II is neither validated nor suited to describe how the
patient’s disease state evolves over time. Therefore other
scores such as the sequential organ failure assessment score
(SOFA) [24, 25] have been developed. The SOFA score is
composed of 6 items that individually score the respiratory,
cardiovascular, hepatic, coagulation, renal and neurologic
system function. Each item ranges from 1 (normal organ
function) to 4 (severely impaired function); items are ad-
ded up resulting in SOFA scores ranging from 6 (no organ
failure) to 24 (most sick) points.
Patients were SOFA scored at admission, day 3, 5 and 10
as well as on the day of ICU discharge. Scores were cal-
culated in retrospect by adding up the number of points as-
signed to each item based on the worst value recorded dur-
ing the specific day [26]. From SOFA scores obtained, the
number of organs in failure (failing organ defined as organ
specific SOFA score ≥3 [24, 25]) was analysed and evalu-
ated for predicting outcome.
Statistics
Data was anonymously manually entered into Excel (Mi-
crosoft), rearranged and analysed by the SPSS (SPSS Stat-
istics 17.0; Chicago, Illinois) and NCSS (NCSS 2007;
Kaysville, Utah) software packages which were also used
for data editing. There were no missing data for baseline
characteristics as well as for the hospitalisation period.
However in 5 patients data collection was not completed
for the one year follow up. In these cases data was entered
as censored at the time point of the last observation for sur-
vival analysis but data was excluded in endpoint analysis.
Survival at one year was the primary endpoint for analysis
and was defined as being alive at day 365 after hospital ad-
mission. For this endpoint we stratified the cohort in pa-
tients having either haematological or solid malignancies.
We also stratified the cohort into subgroups defined by the
number of organs they were found to have in failure at the
specified time points. In all subgroups outcome at one year
was calculated. As statistical models, we used Kaplan-Mei-
er plots and Log rank estimates.
Second endpoints included survival at time points other
than one year after hospital admission, as well as descript-
ive analysis of patient characteristics, therapy delivered and
complications or outcomes in general or concerning their
malignancies (i.e. haematological as compared to solid ma-
lignancies).
To analyse these endpoints we used parametric (Wilcoxon)
analysis for ordinal parameters split up in no more than two
groups and parametric Kruskal-Wallis One-Way ANOVA
on ranks followed by pairwise comparison when more than
two groups of ordinal data were compared, chi-squared
tests for categorical outcomes or proportions or Fisher’s ex-
act test in case of n <5. Calculation of sensitivity and spe-
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cificity together with plotting receiver operator curves and
calculation of the area under the curve (AUCROC) was used
to analyse test performance. Tests used are specified to-
gether with p-values obtained.
Results
Patient population and base line characteristics at ICU
admission
Within the predefined 12 month period, a total of 74 pa-
tients (median age 62 years) with underlying malignancies
were admitted to the ICU and entered our data analysis
(table 1). Of those, 42 (57%) suffered from solid and 32
(43%) form haematological malignancies. Urogenital ori-
gin was most common among solid malignancies (18 pa-
Table 1: Baseline characteristics:
Type of malignancy All Solid1 Haematological2 P value3
Demographics
Nbr. of Patients (%) 74 42 (57) 32 (43)
Age, median yrs (IQR) 62 (50-71) 66 (57-73) 56 (44-65) 0.0084
Male (%) 38 (51) 24 (57) 14 (44) 0.3645
SAPS, median (IQR) 43 (29-64) 39 (28-53) 45 (29-74) 0.2024
SOFA median (IQR) 6 (4-11) 5 (3-9) 8 (5-11 ) 0.0394
Disease status
Newly diagnosed7 (%) 33 (45) 19 (45) 14 (44) 0.8995
Progression / relapse (%) 28 (38) 19 (45) 9 (28) 0.2075
Stable / remission8 (%) 13 (18) 4 (10) 9 (28) 0.0626
Antineoplastic therapy
Chemotherapy (%) 56 (76) 24 (57) 32 (100) 0.0016
Days before ICU (IQR) 14 (2-101) 33 (1-289) 13 (3-28) 0.0454
SCT, BMT9 6 (19)
Month before ICU (IQR) 5.7 (2.7-20)
1 Urogenital (n=18; 43%), lung (n=10; 24%), gastrointestinal (n=7; 17%), head (n=4; 10%), others (n=3; 7%); see also Figure 1
2 Lymphoma (n=17; 53%), acute leukemia (n=12; 38%) and chronic leukemia (n=3; 9%); see also Figure 1
3 Comparing patient groups suffering from solid and hematologic malignancies
4 P value calculated using Wilcoxon Rank-Sum Test
5 P value calculated using CHI-squared test
6 P value calculated using Fisher's exact test
7 Newly diagnosed within the last 3 months before ICU admission
8 Absence of progression of malignancy, partial or complete remission
9 SCT (Autologous stem cell transplant); BMT (Bone Marrow Transplantation)
Table 2: Leading indication for ICU admission:
Type of malignancy All Solid* Haematological* P value*
Nbr. of patients (%) 74 42 (57) 32 (43)
Cardiovascular1 (%) 29 (39) 23 (55) 6 (19) 0.0042
ACS (%) 11 (15) 9 (21) 2 (6) 0.1003
Cardiac arrest (%) 5 (7) 3 (7) 2 (6) 0.9993
Congestion (%) 13 (18) 10 (24) 3 (9) 0.1323
Acute respiratory failure4 (%) 9 (12) 4 (10) 5 (16) 0.4883
lnfection5 (%) 13 (18) 1 (2) 12 (38) 0.0013
Pneumonia (%) 7 (9) 1 (2) 6 (19) 0.0383
SIRS / septic shock (%) 6 (8) 0 (0) 6 (19) 0.0053
Neurological deterioration (%) 6 (8) 4 (10) 2 (6) 0.6923
Postoperative monitoring (%) 8 (11) 4 (10) 4 (13) 0.7253
Other6 (%) 9 (12) 6 (14) 3 (9) 0.7203
Organ dysfunction
Respiratory SOFA ≥ 2 (%) 55 (74) 31 (74) 24 (75) 0.9082
Cardiovascular SOFA ≥ 1 (%) 48 (65) 28 (67) 20 (63) 0.6032
Renal SOFA ≥ 1 (%) 44 (59) 26 (62) 18 (56) 0.8012
Hepatic SOFA ≥ 1 (%) 26 (35) 10 (24) 16 (50) 0.0362
Cerebral SOFA ≥ 2 (%) 17 (23) 9 (21) 8 (25) 0.9342
* Specifications cf table 1
1 all cardiovascular indications not related to SIRS / sepsis / septic shock
2 P value calculated using CHI-squared test
3 P value calculated using Fisher's exact test
4 excluding pneumonia und cardiac lung edema
5 including SIRS, sepsis, septic shock und pneumonia
6 renal and gastrointestinal indications, interventions and others
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tients; 24%), whereas lymphoma (17 patients; 23%) was
most prevalent among haematological malignancies
(fig. 1). At ICU admission, patients with haematological
malignancies were significantly younger (median age of
Figure 2
Survival analysis of patients with malignancies. (A) One year
Kaplan-Meier survival curve stratified by the type of malignancy.
Log rank comparison between groups yielded P = 0.99. (B) Survival
plot stratified by the number of organs in failure. Log rank
comparison between groups yielded P = 0.004 (C) Receiver
operator curve stratified by the type of malignancy (solid, in black;
haematological, in grey) analysing the number of organs in failure
for predicting hospital fatality. AUCROC = 0.86 for haematological
and 0.89 for solid malignancies. (D) Receiver operator curve
stratified by the type of malignancy (solid, in black; haematological,
in grey) analysing the number of organs in failure for predicting 1
year fatality. AUCROC = 0.68 for haematological and 0.69 for solid
malignancies.
Figure 3
Admission SOFA scores and maximal SOFA scores obtained on
day 3, 5 and 10 were stratified by the type of malignancy and
survival status at one year. Data are given as box plots (showing
median, line; central 50%, box and 2.5 and 97.5 percentile,
whiskers) with individual panels for the day of admission (A), day 3
(B), 5 (C) and 10 (D) on the ICU. Parametric ANOVA on ranks
revealed group differences of p = 0.008 (B) and p = 0.044 (C) with *
significant post hoc group comparison (Bonferroni) at the p = 0.05
level.
56 versus 66 years; p = 0.08), had a higher SOFA scores
(8 versus 5; p = 0.039) and were more likely to be on
chemotherapy or have had recent chemotherapy as com-
pared to those with solid malignancies (100% of the pa-
tients versus 57%; p <0.001). In either type of malignancy
around half of the patients had just been diagnosed with the
malignancy (table 1).
The ultimate reason for referral to the ICU was most fre-
quently a cardiovascular event in patients with a solid ma-
lignancy (55% of the admissions) which was significantly
less common in haematological patients (19%; p = 0.004).
In contrast in haematological patients, infection was most
frequently the reason for ICU admission (38% of the ad-
missions) and was significantly less common in patients
with solid malignancies (2%; p = 0.001). Pneumonia (19%
versus 2%, p = 0.047) and sepsis (0% versus 19%, p =
0.009) were also significantly more prevalent among pa-
tients with haematological malignancies (table 2). The dis-
tribution of organ specific SOFA scores was comparable in
either malignancy group except for the significantly more
frequent hepatic disorders found in patients with a haemat-
ological malignancy (50% versus 24%, p = 0.036) when
compared to solid malignancies (table 2).
Evolution during ICU stay
There was a trend for patients with haematological malig-
nancies to stay longer on the ICU which became significant
(median 15 compared to 32 days; p = 0.002) for the total
hospital stay as compared to patients with solid malignan-
cies (table 3). Consistent with their longer hospital stays,
they had significantly less common single organ failure
(34% versus 71%; p = 0.002) but 3 or more organs in fail-
ure more frequently (53% versus 17%, p = 0.002; table 3).
Patients with haematological malignancies were more fre-
quently on a ventilator (75% as compared to 36% in pa-
tients with solid malignancy; p = 0.002), on vasopressors
(66% and 33% respectively; p = 0.012) or received renal
replacement therapy (34% and 10% respectively; p =
0.019) table 3). Nevertheless in either group similarly few
patients had an uncomplicated ICU stay (26% in solid and
34% in haematological malignancy). Complications during
the ICU stay occurred in patients with either type of ma-
lignancy at comparable levels except for significantly more
cases of ventilator associated pneumonia in patients with
haematological malignancy (38% versus 7%; p = 0.0034;
table 3).
Survival-analysis
There were no significant differences in mortality over the
observation period between patients with haematological
and solid malignancies (fig. 2A). Overall ICU mortality
was 26% (19/74) with 17% (7/42) in solid and 37% (12/32)
in haematological malignancies. There were an additional 7
deaths on the ward after ICU demission resulting in a hos-
pital mortality of 35% (26/74) for all patients; 29% (12/42)
for patients with solid, and 44% (14/32) for haematological
malignancy respectively. One year follow up was biased by
the failure of follow up in 5 patients. From these remaining
69 patients 29% (20/69) were alive after one year, 31% (12/
39) with solid and 27% (8/30) with haematological malig-
nancies. Survival was significantly linked to the number of
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organs in failure (fig. 2B) while under intensive care ther-
apy. The curves split according to the number of organs in
failure within the first 100 days. Since the predictive value
of a parameter tested at a specific time point can be es-
timated by calculation of the area under the curve (AUC)
in receiver operator curves (ROC), we calculated AUCROC
for the number of organs in failure for predicting hospital
(fig. 2C) and 1 year (fig. 2D) fatality in patients with sol-
id or haematological malignancies. The number of failing
organs predicted hospital fatality with an AUCROC of 0.87
overall and of 0.86 for patients with solid and 0.89 for pa-
tients with haematological malignancies, whereas predic-
tion was weaker for one year mortality (0.69 for patients
with solid and 0.68 for patients with haematological ma-
lignancies). In order to corroborate this data we calculated
sensitivity and specificity for specific cut off values. These
are listed in table 4.
Serial evaluation of total SOFA scores was proposed to pre-
dict outcome in critically ill patients [26]. We calculated
SOFA scores at admission and for the patients remaining
on the ICU at day 3, 5 and 10 and analysed survival at one
year (fig. 3A-D). Parametric analysis of variance yielded
significantly different SOFA scores among the 4 groups on
day 3 and 5. Post hoc group comparisons on single days
showed a significantly lower SOFA score for one year sur-
vivors suffering from haematological malignancy, for ana-
lyses on days 5 and 10 the study was underpowered.
Discussion
New therapeutic options in oncology significantly prolong
survival and quality of life for many patients with ma-
lignancies but can also cause complications requiring in-
tensive medical care treatment [27]. As a result, increasing
numbers of patients have to make a decision for or against
intensive care treatment with physicians supporting and
advising them. However intensivists have been shown to
often inaccurately predict outcome, especially in patients
suffering from haematological malignancies [28] and the
reliability of admission scores is also discussed controver-
sially [3, 29–31] making the decision on whom to refer to
critical care therapy difficult. The more and more stringent
economic environment together with findings that patients
with malignancies consume more critical care resources
than non-oncological patients [31] further complicate such
decisions. To review our local policy and to test for reli-
ability of scores in our specific setting, we retrospectively
analysed patients with malignancies in our single institu-
tion. We assessed baseline characteristics, indications for
ICU admission, therapy provided together with complica-
tions occurring on the ICU as well as survival over a one
year period.
As in earlier studies [11–17], the main reason for ICU ad-
mission in patients with haematological malignancies was
infection. Infections were mainly pulmonary and most fre-
quent in patients requiring mechanical ventilation (75% of
the patients). Since infections frequently result in sepsis
they also explain the frequent need for vasopressors, renal
replacement therapy and occurrence of liver dysfunction.
In contrast to earlier studies [3], we report higher SOFA
scores on average in haematological compared to solid can-
cer patients. Nevertheless we found that the two groups had
comparable outcomes despite haematological patients hav-
ing higher SOFA scores. These were in part caused by sig-
nificantly more frequent liver dysfunction in haematologic-
al malignancies, a condition linked to especially poor pro-
gnosis [6]. We did not observe worse outcomes in haemat-
oligical as compared to solid malignancy patients. One
possible explanation is the significant age difference (me-
dian age of haematological patients was 10 years younger
than patients with solid malignancies). Age has been shown
to heavily impact outcome in critically ill patients with
malignancies [32]. Whether specific referral policies by
haematologists further introduced a selection bias in our
cohort cannot be clarified in our retrospective single insti-
tution study.
Our study confirms earlier findings [5, 6, 22, 33–36] show-
ing a highly predictive value of the numbers of organs in
failure in predicting outcome. Especially patients with 3 or
more organs in failure were found to have a poor outcome
in terms of hospital and one year survival. Assessment of
the organs in failure is thus a helpful predictor for surviv-
al in patients already admitted to the ICU. We found that
the number of organs in failure was better at predicting sur-
vival at hospital discharge than at one year. Loss of accur-
acy over time could be explained by fatalities caused by the
underlying malignancy and not by the acute condition that
resulted in ICU admission. The constant and high mortal-
ity observed after day 100 of hospitalisation and even in
patients with no or one organ in failure supports this hy-
pothesis. In contrast to scoring the maximal organs in fail-
ure, SOFA scores made on admission and subsequent days
was not suited to predict outcome in our cohort, as reported
earlier and for admissions scores [3, 29, 31].
The relatively small patient population is a major limitation
of our study as well as the retrospective character that can-
not control for selection bias. Similar to previous studies
[1–6, 31] we cannot estimate in how many critically sick
patients referral to the ICU was not desired, not evaluated
or referral was ultimately denied. Thus our observations
and conclusion might only be applied to patients already
referred to an ICU but cannot help to decide who should be
referred to a critical care unit. Further research will be re-
quired to better guide such decisions.
In conclusion we show that overall mortality was high in
patients with malignancies but that one quarter of the pa-
tients survived for more than one year. Whereas admis-
sion SOFA score did not allow identification of patients
with poor outcome, the number of organs in failure allowed
the prediction of hospital fatality and one year survival in
both solid and haematological malignancies. Accordingly
we suggest that in addition to the diagnosis of malignancy
and the potentially curative therapy applied, the severity of
illness quantified as number of organs in failure should also
tailor therapy and guide ICU management in the future.
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Figures (large format)
Figure 1
Relative prevalence of solid and haematologic malignancies. Data is presented as the percentage of specific types of malignancies among the
study population.
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Figure 2
Survival analysis of patients with malignancies. (A) One year Kaplan-Meier survival curve stratified by the type of malignancy. Log rank
comparison between groups yielded P = 0.99. (B) Survival plot stratified by the number of organs in failure. Log rank comparison between
groups yielded P = 0.004 (C) Receiver operator curve stratified by the type of malignancy (solid, in black; haematologic, in grey) analysing the
number of organs in failure for predicting hospital fatality. AUCROC = 0.86 for haematologic and 0.89 for solid malignancies. (D) Receiver
operator curve stratified by the type of malignancy (solid, in black; haematologic, in grey) analysing the number of organs in failure for predicting
1 year fatality. AUCROC = 0.68 for haematologic and 0.69 for solid malignancies.
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Figure 3
Admission SOFA scores and maximal SOFA scores obtained on day 3, 5 and 10 were stratified by the type of malignancy and survival status at
one year. Data are given as box plots (showing median, line; central 50%, box and 2.5 and 97.5 percentile, whiskers) with individual panels for
the day of admission (A), day 3 (B), 5 (C) and 10 (D) on the ICU. Parametric ANOVA on ranks revealed group differences of p = 0.008 (B) and p
= 0.044 (C) with * significant post hoc group comparison (Bonferroni) at the p = 0.05 level.
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